08:53 AM EDT, 09/05/2024 (MT Newswires) -- Hoth Therapeutics ( HOTH ) said Thursday it received positive data for the treatment of epidermal growth factor receptor inhibitor-associated papulopustular eruptions with its therapy HT-001.

In the first human case, the patient was able to stop treatment after one week, the company said, adding that the results mark "a significant advancement" in managing side effects in cancer patients undergoing epidermal growth factor receptor inhibitor therapy.

A phase 2a clinical trial is currently underway to further evaluate HT-001.

Shares of the company were up more than 43% in Thursday's premarket activity.

Price: 1.0000, Change: +0.31, Percent Change: +43.97